NATIXIS ADVISORS, L.P. - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 295 filers reported holding HAEMONETICS CORP in Q3 2018. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.

Quarter-by-quarter ownership
NATIXIS ADVISORS, L.P. ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q3 2023$1,388
+16.2%
15,495
+10.4%
0.00%0.0%
Q2 2023$1,195
+10.8%
14,030
+7.6%
0.00%0.0%
Q1 2023$1,079
-99.9%
13,038
-16.3%
0.00%
-55.6%
Q1 2021$1,729,000
-20.5%
15,578
-15.0%
0.01%
-30.8%
Q4 2020$2,175,000
+31.5%
18,318
-3.4%
0.01%
+30.0%
Q3 2020$1,654,000
-31.9%
18,962
-30.0%
0.01%
-16.7%
Q2 2018$2,430,000
+31.1%
27,086
+6.9%
0.01%
-33.3%
Q1 2018$1,853,000
+24.2%
25,329
-1.4%
0.02%
+20.0%
Q4 2017$1,492,000
+31.6%
25,696
+1.7%
0.02%
+25.0%
Q3 2017$1,134,000
+28.1%
25,275
+12.7%
0.01%
+20.0%
Q2 2017$885,000
+86.7%
22,421
+71.1%
0.01%
+66.7%
Q3 2016$474,000
+35.4%
13,104
+8.6%
0.01%
+20.0%
Q2 2016$350,000
-3.3%
12,067
+16.7%
0.01%0.0%
Q1 2016$362,000
-87.9%
10,338
-85.7%
0.01%
-90.2%
Q2 2015$2,994,000
-33.1%
72,371
-27.4%
0.05%
-35.4%
Q1 2015$4,477,000
-34.2%
99,665
-45.2%
0.08%
-37.8%
Q4 2014$6,801,000
+27.6%
181,740
+19.1%
0.13%
+18.7%
Q3 2014$5,328,000
-38.4%
152,583
-37.7%
0.11%
-13.7%
Q2 2014$8,644,000
+3724.8%
245,025
+4457.8%
0.12%
+3000.0%
Q4 2013$226,000
+9.2%
5,376
+3.4%
0.00%0.0%
Q3 2013$207,000
-1.0%
5,199
+3.1%
0.00%0.0%
Q2 2013$209,0005,0420.00%
Other shareholders
HAEMONETICS CORP shareholders Q3 2018
NameSharesValueWeighting ↓
BEACONLIGHT CAPITAL, LLC 95,033$8,511,0002.84%
Advantage Alpha Capital Partners LP 100,170$8,971,0002.10%
Nitorum Capital, L.P. 395,635$35,433,0001.82%
Summit Creek Advisors LLC 127,600$11,428,0001.68%
Bridge City Capital, LLC 40,559$3,632,0001.67%
AEGON ASSET MANAGEMENT UK PLC 520,408$46,603,0001.05%
Jackson Square Partners, LLC 2,298,190$205,825,0001.03%
Parkman Healthcare Partners LLC 30,147$2,700,0000.76%
TEALWOOD ASSET MANAGEMENT INC 9,154$820,0000.54%
AMERICAN CAPITAL MANAGEMENT INC 159,145$14,253,0000.52%
View complete list of HAEMONETICS CORP shareholders